Sofiva Genomics ,Ltd. Overview
Get informed when a big investor buys or sells
+ Follow2.27%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 6615.TWO is 2.27%. That is below the sector sector average of 11.64%. Investors often review this figure alongside Sofiva Genomics ,Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 6615.TWO currently prints 2.27% for ROE, while the sector average sits near 11.64%. That is roughly 80.5% below the sector mean. Large gaps often invite a closer look at Sofiva Genomics ,Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively Sofiva Genomics ,Ltd. converts resources into returns. At 2.27%, 6615.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 6615.TWO's ROE (2.27%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
